“clinical-trials” Archives

in
Entry Author Date Location
Shire Steps Back in Hemophilia Gene Therapy Race, Scraps Baxalta Drug 08/03/16 Boston
Biogen Buys Ionis Spine Disease Drug For $75M, Eyes FDA Filing 08/01/16 Boston
In a Microbiome Setback, Seres Drug Fails in Phase 2, Shares Crushed 07/29/16 Boston
At Big Hemophilia Meeting, More Data, and Promise, For Gene Therapy 07/28/16 National
Tokai Pharma Shutters Prostate Cancer Drug Trial Early, Shares Crumble 07/26/16 Boston
Tobira Fails Main Goal in NASH Study, But Forges Ahead To Next Trial 07/25/16 San Francisco
Zafgen Restructures, Abandons Obesity Drug Following FDA Meeting 07/19/16 Boston
After Three Deaths, FDA Halts Juno’s Leading CAR-T Trial 07/07/16 Seattle
Alnylam Advances RNAi Drug Results After Two Years of Treatment 07/01/16 Boston
Syros Cuts Price But Bags $50M in IPO to Fuel Cancer Drug Trials 06/29/16 Boston
Moderna Gets $200M More, Deepens Merck Ties With New Cancer Pact 06/29/16 Boston
More Job Cuts at Infinity As AbbVie Sends Back Blood Cancer Drug 06/28/16 Boston
Regulus Shares Crumble As FDA Halts Testing of Hepatitis C Drug 06/27/16 San Diego
After Failed Schizophrenia Trial, Forum Pharma To Shutter This Week 06/27/16 Boston
As Macchiarini Faces Charges, Biostage Forges Ahead With New Tech 06/23/16 Boston
Epizyme Touts Early Data From Key Trial Of Blood Cancer Drug 06/19/16 Boston
Paratek Shares Climb After Antibiotic Clears First Phase 3 Hurdle 06/16/16 Boston
Infinity Closes Research Ops as Blood Cancer Drug Comes Up Short 06/14/16 Boston
Anemia Ups and Downs: Agios Hit On One Drug, Touts Data For Another 06/11/16 Boston
In Race to Relief, Amgen Touts New But Incomplete Migraine Data 06/09/16 San Francisco
Pivoting Again, Catabasis Looks to NASH After Cholesterol Drug Flops 06/07/16 Boston
Biogen’s Nerve Repair Drug Fails MS Study, Shares Fall 06/07/16 Boston
Strata Oncology Closes $12M Round, Aims to Increase Tumor Sequencing 06/06/16 Detroit Ann Arbor
Ocular’s Shares Fall After Eye Treatment Fails Latest Test 06/06/16 Boston
Syros Files For IPO to Push “Gene Control” Drugs Through First Trials 06/06/16 Boston
Two Years After Paying $680M, BioMarin Shelves Duchenne Drug 05/31/16 San Francisco
Amicus Nabs First Approval as EU Gives Green Light to Fabry Drug 05/31/16 New York
Celator Parlays Leukemia Drug Data into $1.5B Buyout From Jazz Pharma 05/31/16 New York
FDA Commish Califf to Big Data Crowd: Flood Of New Treatments Coming 05/26/16 National
Minerva’s Shares Soar on Early Data for Schizophrenia Drug 05/26/16 Boston
Page 2 of 19 « previous page · next page »